Company
History
Months and Years |
Overview |
---|---|
Oct, 2014 | Founded Repertoire Genesis Inc. |
Nov, 2014 | Set up a laboratory in Osaka, Japan |
Dec, 2014 | Immune diversity analysis service was started |
Jun, 2015 | Signed a contract service intermediation agreement with Wako Pure Chemical Industries Ltd. (presently FUJIFILM Wako Pure Chemical Corporation) and designated it as our distributor in Japan |
May, 2016 | Set up a branch office in Tokyo |
Apr, 2017 | Expansion of Osaka Laboratory (Head Office) |
Jun, 2017 | A basic patent on immune diversity analysis was established in Japan (Japanese Patent No. 6164759) |
Oct, 2017 | Two patents were jointly filed with Hiroshima University on the complete replacement technique of T cell receptors that contribute to novel T cell therapy |
Aug, 2018 | A patent on biomarkers for ME/CFS was co-filed with the National Center of Neurology and Psychiatry |
Applied for a patent of amplification technology of TCR/BCR pair gene from a single cell | |
Oct, 2018 | Expansion of Osaka Laboratory (Head Office) |
Nov, 2018 | Relocation of Tokyo Office |
Mar, 2019 | Osaka Laboratory acquired the international standard "ISO/IEC 17025: 2017" accreditation in the field of TCR/BCR repertoire analysis for the first time in the world |
Sep, 2019 | Concluded a comprehensive joint R&D agreement and capital alliance with Zenyaku Kogyo Co., Ltd. |
Oct, 2019 | Started a Collaborative Research Laboratory program named “Next Generation Development of Genome and Cellular Therapy Program” in the Department of Hematology and Oncology at Research Institute for Radiation Biology and Medicine, Hiroshima University |
Mar, 2020 | Concluded a non-exclusive Collaboration and Option to License Agreement with Cellectis SA. on the development of a TCR-T cell product against NY-ESO-1 with the TAL Nuclease technology for cancer immunotherapy |
May, 2020 | A basic patent on neoepitope analysis was established in Japan (Japanese Patent No.6710004) |
Jun, 2020 | Participation in the development project of a comprehensive evaluation method of COVID-19 virus antigen-specific immune responses for the selection of high-risk patients |
Signed a contracted research and development agreement with AMED to establish basic technology for manufacturing highly functional genome-edited T cells | |
Dec, 2021 | A basic patent on TCR/BCR Repertoire Analysis was established in the US (US Patent No. 11203783) |
May, 2022 | Eurofins Scientific SE acquired a majority stake in our company and we became a member of the Eurofins Group |
Sep, 2022 | A patent for a new biomarker for cancer immunotherapy co-filed with Hyogo College of Medicine was granted in Japan (Japanese Patent No.7150280) |
Jun, 2023 | Participation in the development of the AMED project "Research on the development of a comprehensive evaluation method for pathogen antigen epitopes in preparation for disease X and its application to epidemic forecasting" |
Jul, 2024 | Participation in AMED's translational research program "Development of a monovalent vaccine against serotype-specific dengue virus that can inhibit antibody-dependent infection enhancement (ADE)" |